SABS vs. ACHV, RGLS, AGEN, FBIO, CRIS, BOLT, MTEM, AMGN, GILD, and VRTX
Should you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Achieve Life Sciences (ACHV), Regulus Therapeutics (RGLS), Agenus (AGEN), Fortress Biotech (FBIO), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "biotechnology" industry.
SAB Biotherapeutics vs.
Achieve Life Sciences (NASDAQ:ACHV) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk, community ranking and dividends.
Achieve Life Sciences has a net margin of 0.00% compared to SAB Biotherapeutics' net margin of -1,450.14%. SAB Biotherapeutics' return on equity of -94.37% beat Achieve Life Sciences' return on equity.
Achieve Life Sciences has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.
Achieve Life Sciences presently has a consensus target price of $14.80, indicating a potential upside of 378.96%. SAB Biotherapeutics has a consensus target price of $12.40, indicating a potential upside of 251.27%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than SAB Biotherapeutics.
Achieve Life Sciences received 307 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 81.82% of users gave SAB Biotherapeutics an outperform vote while only 70.46% of users gave Achieve Life Sciences an outperform vote.
33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 2.0% of Achieve Life Sciences shares are held by company insiders. Comparatively, 26.5% of SAB Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Achieve Life Sciences has higher earnings, but lower revenue than SAB Biotherapeutics.
In the previous week, Achieve Life Sciences had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 2 mentions for Achieve Life Sciences and 0 mentions for SAB Biotherapeutics. Achieve Life Sciences' average media sentiment score of 0.64 beat SAB Biotherapeutics' score of 0.00 indicating that Achieve Life Sciences is being referred to more favorably in the media.
Summary
Achieve Life Sciences beats SAB Biotherapeutics on 11 of the 16 factors compared between the two stocks.
Get SAB Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SAB Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SABS) was last updated on 1/21/2025 by MarketBeat.com Staff
Free SABS Stock Alerts